Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.59 |
| ▸ | MAOA | P21397 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CALML3 | P27482 | 1/20 | 0.54 |
| ▸ | SDHA | P31040 | 1/20 | 0.54 |
| ▸ | F10 | P00742 | 2/20 | 0.49 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2464074 | 0.89 | MAOB (0.64) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL12317752 | 0.89 | MAOB (0.64) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL14982833 | 0.84 | MAOB (0.72) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL12126884 | 0.84 | MAOB (0.72) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL8570379 | 0.83 | ALDH1A1 (0.42) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL29006109 | 0.79 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL29006111 | 0.79 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL29418180 | 0.79 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL19512263 | 0.79 | MAOB (0.68) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL23699727 | 0.78 | MAOB (0.69) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | disclosed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | disclosed |
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2016-04-14 | — | — | US | disclosed |
| WO-2010084514-A2 | A PROCESS FOR THE PREPARATION OF (5S)-(N)-[[3-[3-FLUORO-4-(4-MORPHOLINYL) PHENYL]-2-OXO-5-OXAZOLIDINYL] METHYL] ACETAMIDE | NEULAND LABORATORIES LTD. (IN) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102064-A1 | IMPROVED PROCESSES FOR THE PREPARATION OF LINEZOLID USING NOVEL INTERMEDIATES | CYP3A5, SBDS, MLYCD | MAOB 951/4885MAOA 522/4885LMNA 1949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.